BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Sep. 15, 2023

View Archived Issues
insightec-exablate-neuro-12-13.png

Insightec secures additional CE mark for Exablate Neuro to treat essential tremors

Insightec Ltd. broadened its CE mark approval for the Exablate Neuro, a focused ultrasound platform which treats essential tremors, to allow patients to have their second side treated. With some 60 million people estimated to be affected by essential tremor globally, Insightec hopes that with both sides treated, patients will have full body relief from tremor and therefore be able to resume everyday activities.

Read More
Blastocyst measurement

Selection based on blastocysts size nearly doubles IVF transfer success

Choosing blastocysts for transfer based on size could give prospective parents a much better chance of success in welcoming a new member to the family, a study published in the Nature portfolio journal Scientific Reports demonstrates. Read More
FDA icons

FDA’s device center continues stream of post-summer draft and final guidances

The U.S. FDA has broken out of the summer guidance doldrums in fine form, inking a series of nine draft and final guidances in the first half of September alone. The latest bolus includes a revised version of a guidance for the breakthrough devices program and two draft guidances for devices for weight loss, giving industry plenty to mull over as the final days of fiscal year 2023 trickle away. Read More
Ketone monitor wearable

Patent update: ASU researchers develop simple test for ketones to measure metabolic rate

Arizona State University (ASU) reported the receipt of a patent for a device with colorimetric sensors for measuring excreted ketones in a body fluid. Additional sensors may be incorporated to measure flow rate of the body fluid, barometric pressure, humidity, and chemicals such as oxygen and carbon dioxide present in the fluid, and a system to measure metabolic rate and respiratory quotient via oxygen consumption rate and carbon dioxide production rate. Read More

Exor-Philips deal tops charts as industry’s largest; overall med-tech deals up 90% YOY

Med-tech deal values continued their upward swing, increasing nearly 90% from last year. Med-tech M&A volume and value remained in a slump compared to the previous two years, though values are higher than 2020.

Read More

Appointments and advancements for Sept. 15, 2023

New hires and promotions in the med-tech industry, including: Heartvista, Nusano, Orion Innovation, Vista.ai. Read More

Financings for Sept. 15, 2023

Med-tech firms raising money in public or private financings, including: Rayzebio. Read More

In the clinic for Sept. 15, 2023

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ondine Biomedical, Organon. Read More

Other news to note for Sept. 15, 2023

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Epigenomics, Motus, New Day Diagnostics. Read More

Regulatory actions for Sept. 15, 2023

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Smartcardia. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

    BioWorld Science
    Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...
  • Medical illustration showing layers of a blood vessel

    Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

    BioWorld Science
    More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing